Adage Capital Partners GP L.L.C. increased its position in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 392.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 279,800 shares of the company's stock after purchasing an additional 223,000 shares during the period. Adage Capital Partners GP L.L.C. owned 0.23% of Guardant Health worth $8,548,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in GH. R Squared Ltd purchased a new stake in Guardant Health during the 4th quarter valued at approximately $26,000. SBI Securities Co. Ltd. acquired a new position in Guardant Health during the 4th quarter worth approximately $43,000. Kimelman & Baird LLC acquired a new position in Guardant Health during the 4th quarter worth approximately $58,000. NewEdge Advisors LLC increased its position in Guardant Health by 13.5% during the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after purchasing an additional 230 shares during the period. Finally, Quantbot Technologies LP acquired a new position in Guardant Health during the 4th quarter worth approximately $80,000. 92.60% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on GH shares. Barclays lowered their price target on Guardant Health from $60.00 to $55.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Guggenheim restated a "buy" rating and issued a $56.00 price target on shares of Guardant Health in a report on Monday, February 24th. Piper Sandler upped their price target on Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Morgan Stanley upped their price target on Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a report on Thursday, March 6th. Finally, Stephens restated an "overweight" rating and issued a $55.00 price target on shares of Guardant Health in a report on Wednesday, March 26th. Twenty analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $49.00.
Read Our Latest Stock Report on GH
Guardant Health Stock Performance
Shares of NASDAQ:GH opened at $47.99 on Tuesday. Guardant Health, Inc. has a 1 year low of $17.52 and a 1 year high of $50.89. The stock has a market capitalization of $5.92 billion, a P/E ratio of -13.48 and a beta of 1.45. The stock has a 50-day simple moving average of $43.35 and a 200-day simple moving average of $37.60.
Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The company had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. Analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.
Guardant Health Profile
(
Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
